Study finds that anti-ERBB2 inhibitors used in breast cancer treatment pose significant risks to pregnancy and fetal health, including higher likelihoods of congenital defects and intrauterine growth restriction. Researchers recommend careful monitoring and possibly discontinuing these drugs during pregnancy despite their effectiveness against cancer.